Morepen Laboratories Ltd - MOREPEN LABS. Share Price

Sector: Pharmaceuticals | ISIN: INE083A01026
₹ 48.90 (-1.81%) icon24 May, 2024, 12:00:00 AM
Open
₹ 49.80
Prev. Close
₹ 49.80
Turnover(lac)
₹ 0.01
Day's High
₹ 50.15
Day's Low
₹ 48.55
52 Wk High
₹ 56.40
52 Wk Low
₹ 25.10
Book Value
₹ 17.43
Face Value
₹ 2.00
Mkt. Cap (Cr.)
₹ 2,499.61
P/E
22.55
EPS
2.17
Div. Yield
0.00

Morepen Laboratories Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 5/24/2024 12:00:00 AM

    ₹ 48.9 -0.90 -1.81
  • Open
  • ₹ 49.8
  • Prev. Close
  • ₹ 49.8
  • Turnover(Lac.)
  • ₹ 0
  • Day's High
  • ₹ 50.15
  • Day's Low
  • ₹ 48.55
  • 52 Week's High
  • ₹ 56.4
  • 52 Week's Low
  • ₹ 25.1
  • Book Value
  • ₹ 17.43
  • Face Value
  • ₹ 2
  • Mkt Cap (₹ Cr.)
  • 2,499.61
  • P/E
  • 22.55
  • EPS
  • 2.17
  • Divi. Yield
  • 0

Morepen Laboratories Ltd Corporate Actions

14 May , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

25 Feb , 2024

12:00 AM

19 Feb , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

24 Jan , 2024

12:00 AM

24 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

26 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

26 Oct , 2023

12:00 AM

05 Sep , 2023

12:00 AM

AGM

Announcement date: 05 Sep , 2023

View Details

14 Aug , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

29 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

29 Jul , 2023

12:00 AM

05 Sep , 2023

12:00 AM

BookCloser

View Details

No Record Found


Morepen Laboratories Ltd News and Update

No Record Found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Morepen Laboratories Ltd SHAREHOLDING SNAPSHOT
26 May , 2024 | 09:11 AM

PROMOTER - TOTAL38.22%

Indian: 38.22%

Foreign: 0%

NON-PROMOTER - TOTAL 61.78%

Institutions: 4.01%

Non-Institutions: 57.77%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Morepen Laboratories Ltd FINANCIALS

View Profit & Loss Graph

Morepen Laboratories Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Morepen Laboratories Ltd

  • Sushil Suri
  • Chairman & Managing Director
  • Manoj Joshi
  • Non-Exec. & Independent Dir.
  • Bhupender Raj Wadhwa
  • Non-Exec. & Independent Dir.
  • Sukhcharan singh
  • Non-Exec. & Independent Dir.
  • Vipul Kumar Srivatava
  • Company Sec. & Compli. Officer
  • Sanjay Suri
  • Whole-time Director
  • Praveen Kumar Dutt
  • Non-Exec. & Independent Dir.
  • Savita
  • Non-Exec. & Independent Dir.

Summary

Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L.The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India. The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally. The company has developed a hi-tech Pharma complex at Morepen Village, Baddi (HP) on 60 acres of land that has various multipurpose pharma facilities for API & finished dosages and a Research Centre.The company was established in the year 1984. The company has filed 14 patents including 6 international PCT applications. The company has filed an international patent on a new amorphous form of the cholesterol-reducing drug Lipitor (Atorvastatin) that is the largest selling drug in the world. During the year 1991-1992, the company set up the new facilities for bulk manufacture of Cephalexin, 7 ADCA and CIMC Chloride at its existing... Read More


Reports by Morepen Laboratories Ltd


Reports by Morepen Laboratories Ltd

Company FAQ

No Record Found